Agenus Inc. (NASDAQ:AGEN) Receives $10.00 Consensus PT from Brokerages

Agenus Inc. (NASDAQ:AGEN) has been given an average rating of “Hold” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $10.00.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a report on Wednesday, January 22nd.

Institutional Trading of Agenus

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new position in shares of Agenus in the 2nd quarter valued at approximately $614,000. Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% in the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 9,422 shares during the period. FMR LLC lifted its stake in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after buying an additional 27,309 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Agenus by 2,271.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock worth $217,000 after buying an additional 37,866 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Agenus during the 3rd quarter worth $1,003,000. Institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

Shares of AGEN stock opened at $3.23 on Tuesday. Agenus has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The stock’s 50-day moving average is $3.26 and its two-hundred day moving average is $4.22. The firm has a market cap of $75.78 million, a P/E ratio of -0.29 and a beta of 1.31.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.